Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,923.00    -49.50 (-2.51%)
Bid:
1,919.00
Ask:
1,920.00
Spread: 1.00 (0.052%)
Market Cap: £77.07b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

24 Feb 2022 16:22

RNS Number : 7637C
GlaxoSmithKline PLC
24 February 2022
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

Chief Scientific Officer and President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

b)

Nature of the transaction

Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account.

 

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$42.6900

1,097.774

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-02-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr H Barron

b)

Position/status

Chief Scientific Officer and President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

b)

Nature of the transaction

Acquisition of ADSs within Dr Barron's GSK 401(k) Plan account.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

$42.6900

197

 

 

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2022-02-22

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHQZLFLLLLFBBK
Date   Source Headline
2nd Dec 20223:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20227:00 amRNSEMA file accepted for momelotinib
2nd Dec 20227:00 amRNSJemperli positive trial in endometrial cancer
1st Dec 20223:00 pmRNSTotal Voting Rights
25th Nov 20224:47 pmRNSPublication of Final Terms of EMTN Notes
24th Nov 20223:00 pmRNSGSK publishes provisional 2023 dividend dates
22nd Nov 20224:00 pmRNSPublication of Supplementary EMTN Prospectus
22nd Nov 20227:00 amRNSBlenrep US Update
21st Nov 20223:30 pmRNSDirector/PDMR Shareholding
18th Nov 20224:00 pmRNSPublication of EMTN Supplementary Prospectus
15th Nov 20224:00 pmRNSBlock listing Interim Review
15th Nov 20223:53 pmRNSFinal results of outstanding Notes Tender Offer
15th Nov 20227:00 amRNSInterim results of outstanding Notes Tender Offer
11th Nov 20227:00 amRNSGSK Update: Zejula 2L in US
10th Nov 20226:10 pmRNSSanofi-GSK COVID booster vaccine approved by EU
10th Nov 20223:30 pmRNSDirector/PDMR Shareholding
10th Nov 20229:00 amRNSBlock Listing Application
8th Nov 20229:26 amRNSLaunch of Tender Offer for outstanding Notes
7th Nov 20227:00 amRNSDREAMM-3 phase III trial for Blenrep
3rd Nov 20221:00 pmRNSPublication of Suppl.Prospcts
3rd Nov 20227:00 amRNSIDMC recommends gepotidacin early efficacy stop
2nd Nov 20227:01 amRNS3rd Quarter Results
2nd Nov 20227:00 amRNSGSK RSV vaccine: US FDA Priority Review
1st Nov 20223:00 pmRNSTotal Voting Rights
28th Oct 20227:00 amRNSEMA validates MAA for cabotegravir LA for PrEP
28th Oct 20227:00 amRNSEMA accepts GSK RSV older adult vaccine for review
27th Oct 20227:05 amRNSGSK announces FDA meeting outcome on daprodustat
27th Oct 20227:00 amRNSContRAst phase III programme for otilimab update
25th Oct 202210:00 amRNSBoard Committee Changes
21st Oct 20227:00 amRNSRSV older adult vaccine submission in Japan
17th Oct 20227:00 amRNSMenveo new single-vial approve by US FDA
17th Oct 20227:00 amRNSMenveo new single-vial approved by US FDA
14th Oct 20222:11 pmRNSDirector/PDMR Shareholding
13th Oct 202212:46 pmRNSDirector/PDMR Shareholding
13th Oct 20229:44 amRNSDirector/PDMR Shareholding
13th Oct 20228:26 amRNSDirector/PDMR Shareholding
13th Oct 20227:00 amRNSEfficacy results for GSK’s older adult RSV vaccine
12th Oct 202211:42 amRNSDirector/PDMR Shareholding
10th Oct 20227:00 amRNSUS FDA approves Boostrix maternal immunisation
7th Oct 20224:38 pmRNSDirector/PDMR Shareholding
7th Oct 20224:24 pmRNSDirector/PDMR Shareholding
3rd Oct 202210:10 amRNSTotal Voting Rights
30th Sep 20225:21 pmRNSDirector/PDMR Shareholding
26th Sep 20225:09 pmRNSDirector/PDMR Shareholding
26th Sep 20227:00 amRNSGSK Chief Financial Officer succession
22nd Sep 20222:00 pmRNSUS FDA ODAC review of Zejula Phase III NOVA trial
22nd Sep 20227:00 amRNSGSK and Spero Therapeutics licence for tebipenem
21st Sep 202211:22 amRNSDirector/PDMR Shareholding
13th Sep 20229:11 amRNSDirector/PDMR Shareholding
9th Sep 20229:11 amRNSPublication of Base Prospectus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.